Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down After Earnings Miss

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) gapped down prior to trading on Wednesday following a weaker than expected earnings announcement. The stock had previously closed at $57.00, but opened at $44.70. Supernus Pharmaceuticals shares last traded at $47.2530, with a volume of 500,729 shares trading hands.

The specialty pharmaceutical company reported $0.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.82 by ($0.36). Supernus Pharmaceuticals had a net margin of 9.70% and a return on equity of 14.22%. The business had revenue of $170.00 million during the quarter, compared to analysts’ expectations of $175.82 million. During the same period last year, the company earned $0.69 EPS. The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. Supernus Pharmaceuticals has set its FY 2025 guidance at EPS.

Wall Street Analyst Weigh In

A number of research firms recently commented on SUPN. Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 17th. TD Cowen raised their price target on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Bank of America started coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price objective for the company. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $63.25.

Insider Buying and Selling

In other news, CFO Timothy C. Dec sold 11,780 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $44.49, for a total transaction of $524,092.20. Following the completion of the sale, the chief financial officer directly owned 1,246 shares of the company’s stock, valued at $55,434.54. The trade was a 90.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bethany Sensenig sold 5,369 shares of the stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $42.25, for a total value of $226,840.25. The SEC filing for this sale provides additional information. Insiders have sold 222,741 shares of company stock worth $10,507,792 over the last 90 days. Company insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. Hantz Financial Services Inc. boosted its holdings in Supernus Pharmaceuticals by 81.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 281 shares during the period. USA Financial Formulas acquired a new stake in Supernus Pharmaceuticals during the 3rd quarter valued at $50,000. Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals by 30.8% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 268 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in Supernus Pharmaceuticals during the 1st quarter worth $41,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in Supernus Pharmaceuticals in the 1st quarter worth $46,000.

Supernus Pharmaceuticals Stock Down 2.6%

The company has a market capitalization of $2.58 billion, a price-to-earnings ratio of 40.02 and a beta of 0.75. The firm has a 50 day moving average price of $48.60 and a two-hundred day moving average price of $39.46.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.